Current position: Full Professor in Pediatrics (scientific/disciplinary sector MED/38: General and Specialized Pediatrics) at the Faculty of Medicine and Surgery of the University of Parma, Italy (since September 1, 2019). Director of Pediatric Clinic in Maternal and Child Department -Azienda Ospedaliero- Universitaria di Parma (since November 1, 2019). Pre-university and university education • Classical high school diploma obtained in 1989 (Liceo ginnasio Zaccaria, Milan). • University education at the Faculty of Medicine of the University of Milan. University internships • Institute of Human Physiology (Prof. Emilio Agostoni): academic year 1991-92. • Pediatric Clinic I (Prof. Paolo Careddu): academic years 1992-93 and 1993-94. • Pediatric Clinic IV (Prof. Nicola Principi): academic year 1994-95. Pre-graduate study awards • Exemption fees for merit throughout the university course. Degree in medicine and surgery • At the University of Milan on 27 July 1995, with 110/110 marks and honors. Thesis title: "Evaluation of the synthesis of IgE in relation to the progression of HIV infection in children" (Supervisor: Prof. Nicola Principi). Specializations • In Pediatrics (1999), at the School of Specialization in Pediatrics III of the University of Milan. • In Infectious Diseases (2006), at the School of Specialization in Infectious Diseases of the University of Milan. Scientific activity The scientific activity began during university studies at the Pediatric IV Clinic of the University of Milan with research on pediatric infectious pathology. It continued after graduation and after specialization, initially at the same institution, subsequently at the UO Pediatria 1 Clinic of the University of Milan, called UO Pediatria at High Intensity of Care on August 19, 2013, then at the Pediatric Clinic of the University of Perugia and, therefore, at the Pietro Barilla Children's Hospital of the University Hospital of Parma on various topics of prevention, diagnosis and treatment of pediatric internal diseases. The main contributions concerned: 1. Vaccines • Immune response years after primary vaccination cycles • Evaluation of the efficacy and cost-benefit ratio of influenza vaccination in children • Evaluation of the efficacy and cost-benefit ratio of pneumococcal vaccines in children • Evaluation of the efficacy and cost-benefit ratio of meningococcal vaccines in children • Impact of different ways of preventing pertussis in children • Epidemiology of papillomavirus (HPV) infections and study of the immunogenicity and safety of HPV vaccination in adolescence • Immunogenicity and safety of vaccinations in the immunocompromised child • Safety, tolerability and efficacy of vaccinations in the child with chronic pathology • Immunogenicity and side effects of vaccinations in preterm infants • Vaccinations in pregnancy for the protection of newborns and infants • Development of the vaccine against respiratory syncytial virus 2. Infectious Diseases - Flu and respiratory viruses • Clinical and socio-economic importance of infections from influenza viruses and in general from respiratory viruses in the various pediatric ages • Study of the genetic susceptibility of the host to complications of influenza, rhinovirus infection and respiratory syncytial virus infection • Phylogenetic analysis of circulating respiratory viruses - Infections with invasive bacteria • Epidemiology, diagnosis, clinical manifestations and therapy of invasive pneumococcal infections • Epidemiology, diagnosis, clinical manifestations and therapy of invasive meningococcal infections - Central nervous system infections • Antibiotic therapy in bacterial meningitis • Antiviral therapy in encephalitis • Use of corticosteroids in bacterial meningitis and encephalitis - Tuberculosis • Epidemiology of tuberculosis in children and creation of the Italian Register of tuberculosis in pediatrics • Sensitivity and specificity of new diagnostic methods in children • Treatment of multidrug-resistant tuberculosis in children - Respiratory and intestinal microbiome • Impact of the respiratory and intestinal microbiome in recurrent respiratory infections and allergic diseases • Role of the intestinal microbiome in neurological and psychiatric diseases - HIV infection • Vertical transmission of the infection • Natural history of infection in children • Antiretroviral therapy • Prophylaxis of opportunistic infections • Management of the social-welfare problems of the children of HIV-positive women - Immunocompromised host infections other than HIV • Epidemiology, diagnosis, clinical manifestations and therapy in the oncohematological child and in the transplanted child - Rare and emerging infections • Lyme disease in children • Prevention and treatment of infections in the traveling child • Prevention and therapy of nosocomial infections in pediatrics - Anti-infectious therapy • Pharmacokinetic studies of new antiinfectives in neonatal sepsis Antimicrobial approach aimed at serious infections in neonatal intensive care • Surveillance of the use of antibiotics for the treatment of infectious diseases in wards and pediatric clinics • Empirical anti-infective approach of choice in pediatric ICU • Prophylaxis and perioperative therapy in the newborn and operated child • Pharmacokinetics and pharmacodynamics of new antibiotics and antivirals 3. Pneumology - Community pneumonia • Etiology, diagnosis and therapy of community-acquired pneumonia • Impact of new respiratory viruses (metapneumovirus, coronavirus, bocavirus, rhinovirus, enterovirus) in children with community pneumonia • Role of Streptococcus pneumoniae in bacteraemic pneumonia • Role of Mycoplasma pneumoniae and emergence of antibiotic resistant strains in the child with community pneumonia • Therapeutic plans to be used in community-acquired pneumonia based on emerging pathogens and new antibiotic resistance issues • Follow-up of children with severe pneumonia and analysis of risk factors for the development of bronchiectasis - Bronchiolitis • Role of the respiratory syncytial virus in affecting the remodeling of the airways in the newborn and infant with bronchiolitis • Impact of new respiratory viruses (metapneumovirus, coronavirus, bocavirus, rhinovirus, enterovirus) in the infant with bronchiolitis - Bronchial asthma • Etiology, diagnosis and therapy of bronchial asthma • Genetic and epigenetic susceptibility in the child with bronchial asthma • Role of macrolides in the therapeutic approach to the child with bronchial asthma • Role of monoclonal antibodies in the treatment of severe bronchial asthma -Cystic fibrosis • Role of different pathogens in respiratory exacerbations • Study of resistance to viruses and bacteria anti-infectives 4. Allergy - Respiratory allergy • Impact of vaccines and immunostimulants in the prevention of respiratory allergy - Allergy to drugs • Study of allergy to antibiotics • Study of allergy to antipyretics - Skin allergy • Study of risk factors for the development of atopic dermatitis • Role of viral agents in urticaria 5. Immunology - Immunogenetics • Impact of polymorphisms of toll-like receptors in the immune response of the preterm infant • Role of innate immunity in susceptibility to infectious diseases in children - Primary and secondary immunodeficiencies • Development of neonatal screening tests for the early identification of primary immunodeficiencies • Prevention of infections in pediatric patients with primary or secondary immunodeficiencies 6. Endocrinology and diabetology -Endocrinology • Early and late puberty • Hypogonadotropic and hypergonadotropic hypogonadisms • Congenital and acquired hypothyroidism, hyperthyroidism • Short stature and GH deficiency • Turner syndrome, Noonan syndrome, Klinefelter syndrome - Diabetology • Type 1 diabetes mellitus • Type 2 diabetes mellitus • Occasional hyperglycaemia 7. Rheumatology Immune-mediated complications of Streptococcus pyogenes infections • Kawasaki disease • Role of infectious agents in juvenile idiopathic arthritis • Role of infectious agents in systemic lupus erythematosus • Role of infectious agents in hemophagocytic syndrome • Immunogenicity and safety of vaccinations in patients with autoimmune diseases • Therapy with biological drugs and infectious risk 8. Rare diseases - Epidermolysis bullosa • Multidisciplinary approach to the child with epidermolysis bullosa • Hematological and nutritional aspects in the child with epidermolysis bullosa • Innovative therapies in skin lesions that do not respond to standard treatment - Rubinstein-Taybi syndrome • Genotype-phenotype correlations in the child with Rubinstein-Taybi syndrome - Neurofibromatosis • New clinical manifestations of neurofibromatosis in children • Child-adult transition in the patient with neurofibromatosis - Metabolic diseases • Unusual clinical presentations in children • Safety and immunogenicity of vaccinations in relation to the type of metabolic disease - Other rare diseases • Identification of new genes associated with mental retardation • Gene study of epileptogenic encephalopathies 9. Otolaryngology • Etiology, diagnosis and therapy of acute pharyngotonsillitis • Possibility of short therapies with oral cephalosporins in streptococcal pharyngotonsillitis • Etiology, diagnosis and treatment of acute otitis media • Prevention of recurrent respiratory infections The following were coordinated: 1. studies on the efficacy, safety and tolerability of vaccinations; 2. epidemiological research on the role of viruses and bacteria in the main infections of the pediatric age; 3. controlled clinical trials on the optimal schemes for the treatment of infectious diseases, pneumological diseases, allergic diseases and type 1 diabetes in children. Furthermore, the following research periods have been spent at foreign research facilities: • March 2007 -> Southwestern Medical Center, University Hospital and Clinic, Dallas, TX, USA; • February 2009 -> St George's Medical Center, London, UK; • July 2010 -> Kiremba Hospital, Kiremba, Burundi, Africa. The main international collaborations concern research activities in pediatric infectious disease, pneumology and immunology and involve the Children's Hospital of Dallas (TX, USA), the Health Protection Agency of London (UK), the Erasmus MC of Rotterdam (The Netherlands), the Division of Clinical Virology of the University of Groningen (The Netherlands), St George's Hospital Medical School in London (UK) and the University of Oxford (UK). From 1 September 1997 to 11 December 2000 she was the head of the research laboratory of the Pediatric Clinic IV of the University of Milan; from 12 December 2000 to 27 December 2016 she was the head of the research laboratory of the UO Pediatria 1 Clinic of the University of Milan, called UO Pediatria High Intensity of Care since 19 August 2013. The two laboratories under her guidance in the main Italian multicenter studies have become the reference for: 1. serological and molecular biology assays for the research of Mycoplasma pneumoniae and Streptococcus pneumoniae; 2. identification of common respiratory viruses (respiratory syncytial virus, influenza viruses, adenoviruses, parainfluenza viruses, rhinoviruses) and emerging (metapneumovirus, coronavirus, bocavirus, enterovirus); 3. evaluation of humoral and cell-mediated immune response to combined vaccines; 4. studies on the genetics of the host in response to different types of infection. In 2012, Prof. Esposito identified two new Enteroviruses: enterovirus C-117 and enterovirus C-118 (http://www.picornastudygroup.com/types/enterovirus/ev_types.htm). From 1 January 2017 to 31 August 2019, at the Santa Maria della Misericordia Hospital of the University of Perugia, she directed the following laboratories: • Molecular Genetics Laboratory (Regional Reference Laboratory for the Diagnosis of Cystic Fibrosis); • Postnatal Cytogenetics Laboratory. In addition, in October 2016 the Clinical Trial Unit directed by Prof. Esposito at the IRCCS Ca 'Granda Hospital Maggiore Policlinico Foundation, University of Milan, Milan, and in September 2017 the Clinical Trial Unit directed by Prof.ssa Esposito at the Santa Maria della Misericordia Hospital, University of Perugia, Perugia, have received accreditation from AIFA for conducting phase 1 clinical studies in pediatric age. Summary of the published works The research activity resulted in 710 publications in extenso in international journals with an overall impact factor (I.F.) of 2,791,723 (Journal Citation Reports referring to the year of publication). • Average Impact Factor> 4 for international publications. • h index of 65 (Google Scholar), 50 (Scopus). • Number of citations equal to 17,993 (Google Scholar), 11,690 (Scopus). • Prof.ssa Esposito is in rank 56 of the Top Italian Scientists for Clinical Sciences: http://topitalianscientists.org/TIS_HTML/Top_Italian_Scientists_Clinical_Sciences.html In addition, we highlight: • Articles in nationally distributed periodicals 531 • Nationally distributed volumes 5 • International circulation volume 1 • Chapters on international circulation volumes 10 • Chapters on national circulation volumes 36 • Disclosure articles 266 • 1,382 invitations to invitations to congresses of Scientific Societies of which 631 invited invitations to congresses of International Scientific Societies and 751 invited invitations to congresses of National Scientific Societies Teaching activity Didactic activity carried out in the context of the teaching of General and Specialized Pediatrics of the Faculty of Medicine of the University of Milan: • from the academic year 1999-2000 to the academic year 2016-2017 she also collaborated in practical exercises and guides students in setting up and discussing their theses by participating in the graduation sessions as co-supervisor; • from the academic year 2000-2001 to the academic year 2016-2017, in addition to the assignments listed above, she carried out lessons and tutorial activities (exercises, seminars, discussion of clinical cases), being part of the commissions for the profit exams and participating at graduation sessions as co-supervisor; • from 10 December 2002 to 30 September 2005 she carried out all the above assignments as University Researcher of General and Specialistic Pediatrics (scientific / disciplinary sector MED / 38) of the Faculty of Medicine and Surgery of the University of Milan (related at the Institute of Pediatrics); • from the academic year 2003-2004 to the academic year 2016-2017 she was President of the Elective Course "Antibiotic Therapy in Pediatrics" of the Faculty of Medicine and Surgery of the University of Milan (duration: 40 hours, equal to CFU 2 ); • from 1 October 2005 to the 2016-2017 academic year shehas carried out all the above assignments as Associate Professor of General and Specialized Pediatrics (scientific / disciplinary sector MED / 38) of the Faculty of Medicine and Surgery of the University of Milan, participating in graduation sessions as a supervisor and co-supervisor; • from the academic year 2006-2007 to the academic year 2016-2017 she was President of the Elective Course "Emergencies in Pediatrics" of the Faculty of Medicine and Surgery of the University of Milan (duration: 40 hours, equal to CFU 2) ; • from the academic year 2007-2008 to the academic year 2010-2011 she was the President of the teaching course of General and Specialist Pediatrics (scientific / disciplinary sector MED / 38) at the Central Pole - Line H of the Faculty of Medicine and Surgery of the University of Milan and was the chairman of the examining commission of the related profit exams, also holding lessons for the courses of the Central Pole and the San Donato Pole; • from the academic year 2011-2012 to the academic year 2016-2017 she was the President of the teaching course of General and Specialized Pediatrics in English (Pediatrics: scientific-disciplinary sector MED / 38) - Humanitas Line of the Faculty of Medicine and Surgery of the University of Milan and sheis the chairman of the jury for the related profit exams; • in addition to the Pediatrics course, she continued to carry out lessons for the courses of the Central Pole and the San Donato Pole of the University of Milan and from 2010 to the 2016-2017 academic year she was supervisor of an average of 6 theses of degree for academic year. Didactic activity carried out within the School of Specialization in Pediatrics of the Faculty of Medicine of the University of Milan: • in the academic year 2000-2001 she carried out tutorial activities; • in the academic year 2001-2002 she was a contract professor, carrying out lectures and tutorial activities (exercises, seminars, discussion of clinical cases) and being part of the commissions for profit exams; • from the academic year 2002-2003 to the academic year 2004-2005 she carried out lessons and tutorial activities (exercises, seminars, discussion of clinical cases), being part of the committees for the profit exams and participating in the specialization sessions as a co-supervisor in as University Researcher of General and Specialist Pediatrics (scientific / disciplinary sector MED / 38) of the Faculty of Medicine and Surgery of the University of Milan; • from the academic year 2004-2005 to the academic year 2016-2017 she was responsible for the "Pediatric infectious diseases" course (duration: 6 hours, addressed to the first and second year of the school); • from the academic year 2005-2006 to the academic year 2016-2017 she has carried out all the above assignments as Associate Professor of General and Specialistic Pediatrics (scientific-disciplinary sector MED / 38) by the Faculty of Medicine of the University of the Studies of Milan, participating in the specialization sessions as a speaker or co-supervisor; • from the 2013-2014 academic year to the 2016-2017 academic year, she was the educational coordinator of the Polo (Central Pole) for pediatric specialists. Teaching activity carried out within the Degree Course of Orthoptist and Ophthalmology Assistant of the University of Milan: • from the academic year 2003-2004 to the academic year 2016-2017 she was the holder of the teaching of General and Specialized Pediatrics (scientific-disciplinary sector MED / 38) of the integrated course of interdisciplinary medical-specialist sciences (duration: 20 hours, equal to 2.5 CFU); it also guides students in setting up and discussing degree theses by participating in graduation sessions as co-supervisor. Didactic activity carried out as part of the Degree Course in Nursing Pediatrician of the University of Milan: • from the 2009-2010 academic year to the 2016-2017 academic year she was the teacher of Infectious Diseases in Pediatrics (duration: 10 hours). Postgraduate courses of the University of Milan for which she was proposing and responsible: • from the academic year 2011-2012 to the academic year 2016-2017 she carried out every two years as head of the specialization course in Emergency-urgency in developmental age at the University of Milan; • from the 2012-2013 academic year to the 2016-2017 academic year, she carried out the two-year post-graduate course in Ultrasound in neonatal and pediatric age at the University of Milan as manager. Didactic activity carried out at the University of Perugia: • from the 2017-2018 academic year to the 2018-2019 academic year, she was the Director of the General and Specialistic Pediatrics Course of the School of Medicine of the University of Perugia, supervising more than 15 degree theses per year as supervisor academic; • from the 2017-2018 academic year to the 2018-2019 academic year, she was the Director of the General and Specialized Pediatrics Course of the School of Dentistry of the University of Perugia; • from May 2017 to August 2019 she was the contact person for the framework agreement of the University of Perugia-University of Chile; • in the academic year 2017-2018, she was responsible for the visiting professors program of the University of Perugia of Prof. Miguel O'Ryan (Chile) and Federico Martinon Torres (Spain); • from the 2017-2018 academic year to the 2018-2019 academic year, she was tutor vautatore for the internship in medicine for the state qualification exams to exercise the profession of Medical Surgeon University of Perugia. Didactic activity carried out at the University of Parma: • from the 2019-2020 academic year, she is the Director of the General and Specialized Pediatrics Course and of the Emergency Pediatrics Course of the School of Medicine and Surgery of the University of Parma; • from the 2019-2020 academic year, she is the Director of the Course of Sports Pathology in Children in the Degree Course in Motor Sciences, Sport and Health of the University of Parma; • from the 2019-2020 academic year, she is the Director of the Pediatrics Course in the Physiotherapy Degree Course of the University of Parma; • from the 2019-2020 academic year, she is the Director of the Pediatrics Course in the Obstetrics Degree Course of the University of Parma; • from the academic year 2019-2020, she is the Director of the Pediatrics Course in the Degree Course in Speech Therapy of the University of Parma. Didactic activity carried out at the Specialization School in Pediatrics of the University of Perugia: • from December 28, 2016 to August 31, 2019, she was the Director of the School of Specialization in Pediatrics of the University of Perugia (n. Of specializing students: 30). Doctorate courses for which she has taught guiding: • from the academic year 2010-2011 to the academic year 2012-2013 she followed the University of Milan's University of Milan as a lecturer in practice • from the 2013-2014 academic year to the 2016-2017 academic year, she was part of the professors of the PhD program Epidemiology, Environment and Public Health; • from the 2015-2016 academic year to the 2016-2017 academic year, she was a member of the Board of the PhD course Epidemiology, Environment and Public Health; • from the 2017-2018 academic year, she is one of the teachers of the Doctorate Biology of Systems in Immune and Infectious Pathologies of the University of Perugia. Postgraduate courses of the University of Perugia: • from the academic year 2018-2019, she is the proponent and coordinator of the post-graduate course in preclinical and clinical research; • from the academic year 2018-2019, she is Professor at the II level Master in "Unique and Global Nutritional Health - One global Health Nutrition". Other Specialization Schools for which she has carried out and is a guide teacher: • from the academic year 2010-2011 to the academic year 2016-2017, she coordinated the clinical activity in pediatrics at the School of Specialization in Genetics of the University of Milan; • from the 2015-2016 academic year to the 2016-2017 academic year, she was part of the teaching staff of the School of Specialization in Pediatric Surgery of the University of Milan; • from the 2015-2016 academic year to the 2016-2017 academic year, she was part of the teaching staff of the Specialization School in Thoracic Surgery of the University of Milan from the 2015-2016 academic year to the 2016-2017 academic year , was part of the teaching staff of the School of Specialization in Thoracic Surgery of the University of Milan; • in the 2018-2019 academic year, she was part of the teaching staff of the School of Specialization in Obstetrics and Gynecology of the University of Perugia. Didactic activity carried out in foreign universities: • from the academic year 2009-2010 (continues to this day), she participates as a teacher in the Pediatric Infectious Diseases Diploma of the University of Oxford, UK; • in November 2019, she lectured as an invited professor at Sechenov University in Moscow; • from the academic year 2009-2010 to the academic year 2012-2013, she participated as invited professor in the refresher lessons in pediatric infectious disease at St George's University in London, UK; • in March 2007, as invited professor, lectured at the Pediatric Infectious Diseases Division of the Southwestern Medical Center, University Hospital and Clinic, in Dallas, TX, USA; • in February 2008, as invited professor, she participated in a round table on nosocomial infections at the University Hospital of Geneva (Geneva, Switzerland); • in October 2014, she served on the PhD Commission at the University of Groningen (Groningen, the Netherlands); • in July 2016, as invited professor, she did teaching in pediatric infectious disease for the University of Turku in Finland. Other didactic activity: • from the academic year 1997-1998 she was invited to frequently give reports and lessons on pediatric and infectious disease topics at the main National and International Congresses of Pediatrics and Infectious Diseases; • · since the academic year 1997-1998 she has taught Antibiotic Therapy and Infectious Disease Courses as part of the training programs of the Italian Society of Pediatrics; • since the academic year 1999-2000 she has held reports and seminars within the Theoretical-Practical Courses of Pediatric Otolaryngology organized by the Italian Society of Pediatric Infectivology; • in the academic year 1999-2000 she participated in the teaching activity of the School of Specialization in Infectious Diseases of the Faculty of Medicine and Surgery of the University of Milan; • in the academic year 1999-2000 she participated in the teaching activity in the Postgraduate Course in "Emerging and Re-emerging Pediatric Infectious Diseases" of the University of Florence; • in the academic year 2003-2004 she carried out as an instructor the training courses on SARS of the Lombardy Region at the Clinical Institutes of Improvement; • from the academic year 2006-2007 to the academic year 2009-2010 she was a teacher at the integrated course C1 (integrated course of systems of IT applications for applied medical teaching) of the Master's degree in distance learning in medicine; • since September 2016, she has been carrying out emergency-urgency training activities as head of the SIMEUP Milan Pediatrics Emergency Center (EMiPed); • in October 2016, she worked as a Mentor for specialists interested in pediatric infectious disease for the Infectious Disease Society of America (IDSA) in New Orleans (LO, USA). Assistance activity • Trainee at the Pediatric IV Clinic of the University of Milan: from November 1, 1995 to October 31, 1999. • Internal university doctor at the Pediatric Clinic IV of the University of Milan: from November 1, 1999 to March 12, 2000. • 1st level alternate medical director at the IV Pediatric Clinic of the L. Sacco Hospital in Milan: from 13 March 2000 to 12 November 2000. • 1st level medical officer in charge at the IV Pediatric Clinic of the L. Sacco Hospital in Milan: from 13 November 2000 to 11 December 2000. • 1st level medical director in charge of the Pediatric Clinic I of the Clinical Institutes of Milan: from 12 December 2000 to 31 July 2001. • 1st level medical director at the Pediatric Clinic I of the Clinical Institutes of Milan: from 1 August 2001 to 9 December 2002. • University researcher with an agreement with the Pediatric Clinic I of the Clinical Institutes of Improvement in Milan: from 10 December 2002 to 31 January 2005. • Head of the outpatient infectious disease service and consultancy in infectious disease at the Pediatric Clinic I of the Clinical Institutes of Improvement in Milan: from 10 December 2002 to 31 January 2005. • University researcher with an agreement with the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan: from 1 February 2005 to 30 September 2005. • Head of the Reference Center for Pediatric AIDS of the Lombardy Region at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Ospedale Maggiore Policlinico Foundation, Milan: from 1 February 2005 to 27 December 2016. • Head of the outpatient infectious disease and immunoprophylaxis service and consultancy in infectious disease at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Hospital Maggiore Policlinico Foundation, Milan: from February 1, 2005 to December 27, 2016. • Head of the Center for the traveling child at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan: from 1 May 2005 to 27 December 2016. • Adjunct associate professor at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan: from 1 October 2005 to 27 December 2016. • Head of the Pediatric Infectivology Simple Operative Unit at the UOC Pediatrics 1 Clinic of the IRCCS Ca 'Granda Maggiore Maggiore Policlinico Hospital, Milan: from December 19, 2007 to December 27, 2016. • Deputy director of the Pediatrics 1 Clinic of the IRCCS Ca 'Granda Hospital Maggiore Policlinico Foundation, Milan: from 1 July 2006 to 29 November 2010. • Head of the Regional Reference Center for Lyme disease in children: from 1st January 2011 to 27th December 2017. • Head of the Multidisciplinary Center for epidermolysis bullosa at the IRCCS Ca 'Granda Maggiore Policlinico Hospital: from March 1, 2012 to December 27, 2016. • Head of the SIMEUP Center for the execution of BLS, PBLS and PEARS: from September 1, 2016 to December 27, 2016 in Milan, from December 28, 2016 to August 31, 2019 in Perugia and from September 1, 2019 and still continues in Parma. • Direction of the Pediatrics Unit 1 Clinic of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan, named since August 19, 2013 High Intensity Care Pediatrics Unit: from November 30, 2010 to August 18, 2012 as f.f. of Complex Unit and from 19 August 2013 to 27 December 2016 as Director of Departmental Unit. • Director of the SC Pediatric Clinic of the University of Perugia from 1 January 2017 to 31 December 2018; • Director of the Umbria Regional Center for Diabetes in children and member of the Diabetes Inter-company Group ASL 1 Umbria: from 1 January 2017 to 31 December 2018; • Director of the Pediatric Clinic UOC at the Pietro Barilla Children's Hospital of the University Hospital of Parma: from November 1, 2019 and continues today. Managerial training course for Manager of Complex Structure (Code DSC1701) in 2017-2018 at PoliS Lombardia with discussion on May 15, 2018 of a project work entitled "Proposal of an inter-company Umbrian maternal-child network (RIUMI)" ( Guide teacher: Dr. L. Macchi; Tutor: Dr. A. Zoli). Management training course for Director of Healthcare Structure carried out in 2019 at PoliS Lombardia with discussion on May 15, 2018 of a project work entitled "The relationship between Socio-Territorial Healthcare Companies (ASST) and Health Protection Agencies (ATS) in the path of reorganization of the offer network in accordance with Ministerial Decree (DM) 70/2015 "(Teacher guide: Dr. Marco Bosio). Scientific responsibility for international and national research projects admitted to funding on the basis of competitive calls for peer review Internationally, she was responsible for workpackage in the following projects: • DG Sanco project No. A / 101039 in the Second Program of Community Action in the Field of Health (2008-2013) - Antibiotic resistance and prescribing in European children (duration: 60 months); • ERC (European Research Council) Advanced Grant 2009, proposal no. 250290 - The hygiene hypothesis: revisiting the concept by integrating epidemiology and mechanistic studies: case-control study "(duration: 48 months); She was responsible for workpackage in the following projects: • No. 242146 in FP7-HEALTH-2009 - European multicenter network to evaluate PK, safety and efficacy of meropenem in neonatal sepsis and meningitis (duration: 48 months); • H2020-FTIPilot-2015-1- Fast tracking market adoption of a novel immune-based diagnostic for improving antibiotic stewardship: automation, piloting and health economics (AutoPilot-Dx; duration: 28 months). He is responsible for workpackage in the following project: • IMI-JU-2013 - Standardization and Development of Assays for Assessment of Influenza Vaccine Correlates of Protection (duration: 48 months). At the national level, it participated in the MIUR project No. 2005068289_001 entitled "Influenza vaccination in children: vaccination coverage in children with chronic and healthy diseases and vaccine efficacy in the epidemic period" (duration: 36 months). She was the scientific director of the following regional competitive tenders in Umbria: - Role of Aspergillus fumigatus in the respiratory pathology of children and adolescents with cystic fibrosis funded by the Cassa di Risparmio di Perugia Foundation (duration: 12 months); - Pediatric medical record within the electronic health record (duration: 12 months). She also coordinated the following projects as principal investigator: • RF Young Researchers Call 2007 (Ministry of Labor, Health and Social Policies) "Impact of influenza and immunogenicity and efficacy of influenza vaccination in children: clinical and socio-economic evaluation in hospital and in the territory" (duration: 48 months) ; • Young Researchers RF 2009 Call (Ministry of Labor, Health and Social Policies) "Genetic variants and susceptibility to severe and / or recurrent lower respiratory tract infections with wheezing in children" (duration: 48 months). At regional level, she coordinated the pediatric workpackage in the following project: • "Evaluation and monitoring of HPV infection and related diseases in women at high risk for cervical cancer" (duration: 60 months). She is currently responsible for workpackage: • in the project financed by the Cassa di Risparmio di Perugia on the role of Aspergillus fumigatus in the respiratory pathology of children and adolescents with cystic fibrosis (duration: 24 months); • in the A.R.C.O. funded by the Umbria Region on the electronic health record in children (duration: 12 months). At the IRCCS Ca 'Granda Ospedale Maggiore Policlinico Foundation, she coordinated the following competition project in 2013-2014 which was the winner: Serum microRNAs as new biomarkers of response to vaccination in healthy infants (duration: 24 months). He also supervised the 2015-2016 competition project won by Dr. Samantha Bosis underway at the High Intensive Care Pediatric Unit: Genetic polymorphisms and susceptibility to invasive infections in neonatal and pediatric age (duration: 24 months) . Scientific responsibility as principal investigator in other research projects • Multi-center, randomized, blinded, controlled study to evaluate the clinical efficacy against chickenpox of the live attenuated varicella vaccine against GlaxoSmithKline Biologicals (VarilrixTM) administered as a single dose and of the combined measles-mumps-rubella vaccine- chickenpox of GlaxoSmithKline Biologicals (Priorix - Tetra) administered in two doses to healthy children during the second year of life (OKAH179 & Ext) GlaxoSmithKline (GSK) Biologicals (2006-2016) • Descriptive epidemiological study of community pneumonia in children in the first years of life hospitalized in Italy: comparison between two different methods of diagnosis (2010-2012) • Evaluation and monitoring of HPV infection and related diseases in women at high risk for carcinoma of the uterine cervix Lombardy Region (2010-2014) • Prospective open-label evaluation of the pharmacokinetics / pharmacodynamics and safety of oseltamivir (Tamiflu) in the treatment of infants from 0 to <12 months with confirmed influenza infection (2010-2012) • Primary, multicenter, Phase IIIb, open label, randomized clinical trial, aimed at evaluating the immunogenicity and safety of the HPV - 16/18 L1 VLP AS04 vaccine of GlaxoSmithKline (GSK) Biologicals administered to healthy girls of 9 -14 (2010-2012) • A phase III, randomized, observer - blind, controlled, multi - center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD® versus control vaccines in unprimed healthy subjects aged 6 to 72 months (2010- 2011) • A phase 2b, open label, randomized, parallel-group, multi-center, study to evaluate the safety, tolerability and immunogenicity of Novartis meningococcal B recombinant vaccine when administered with or without routine infant vaccinations to healthy infants according to different immunization schedules ( 2010-2012) • A phase 2b, open label, multi-center, extension study to evaluate the safety, tolerability and immunogenicity of a booster dose of Novartis meningococcal B recombinant vaccine administered at 12, 18 or 24 months of age in subjects who previously received a three- dose primary series of the Novartis meningococcal B Recombinant Vaccine as Infants in study V72P12 (V72P12E1) (2011-2013) • A phase 3, partially blinded, randomized, multi-center, controlled study to evaluate immunogenicity, safety and lot to lot consistency of Novartis meningococcal B recombinant vaccine when administered with routine infant vaccinations to healthy infants (V72P13) (2011-2013) • A phase 3, open label, multi-center, extension study to evaluate the safety, tolerability and immunogenicity of a booster dose of Novartis meningococcal B recombinant vaccine when administered as a booster at 12 months of age or as a two-dose catch- up to healthy infants who participated in study V72P13 (V72P13E1) (2011-2013) • A phase III randomized, open label, multicenter, parallel group clinical trial in children aged 6-36 months to compare the immunogenicity and safety of a single 0.5 ml dose of Inflexal V compared to two 0.25 mL doses of Inflexal V administered according to a 0/4 week dosing schedule (2011-2012) • Phase 2 partially observer-blind randomized controlled multicenter dose-ranging and formulation-finding study to evaluate the safety and immunogenicity of a new recombinant type B Novartis meningococcal vaccine when administered concomitantly with routine vaccines to 2-month-old children age (2011-2013) • Impact of respiratory viruses in cystic fibrosis patients hospitalized for respiratory exacerbations and role of vitamin D deficiency in conditioning the risk and severity of serious viral infections • Monitoring of infections from influenza viruses and other respiratory viruses in children (2011-2012) • Polymorphisms and susceptibility to severe and / or recurrent lower respiratory tract infections with bronchospasm in children (2011-2016) • Impact of environmental pollution on a pediatric population with recurrent wheezing or bronchial asthma (2011-2012) • Genetic polymorphisms and susceptibility to serious and / or recurrent lower airway infections with pediatric bronchospasm (2011-2012) • Epidemiological study on the prevalence of Lyme disease in children (2011-2012) • Study on the immunogenicity and safety of the live attenuated vaccine against measles, mumps, rubella, varicella of GlaxoSmithKline Biologicals (PriorixTetraTM) co-administered with the MenC conjugate vaccine (Meningitec, Wyeth Lederle) in healthy children (2011-2013) • Open-label, phase 3 multicenter extension study to evaluate persistence and antibody response to a third or fifth dose of Novartis recombinant antimeningococcal B vaccine in 4-year-old children who have already participated in study V72P12E1 (2012-2014 ) • Impact of immunostimulant therapy on the immune response to influenza vaccination in children with a history of recurrent respiratory infections or recurrent otitis media (2012-2014) • Immunogenicity, safety and tolerability of influenza vaccination in children and adolescents with metabolic diseases (2012-2014) • Definition of new inflammatory markers of severity and etiology in the child with community pneumonia (CAP) and their correlation with the pulmonary ultrasound parameters (2012-2014) • Study on the safety and efficacy of the combination of inhaled fluticasone propionate and inhaled salmeterol compared to inhaled fluticasone propionate in the treatment of adolescent and adult subjects with severe asthma (2012-2014) • Prospective observational study on the immunogenicity and safety of HPV vaccination in adolescents with autoimmune diseases (2012-2013) • Randomized, double-blind, randomized versus placebo study on the efficacy and tolerability of rhinogermin in the preventive therapy of acute otitis media in the pediatric population with a history of recurrent acute otitis media (2013-2014) • Nutritional status of hospitalization and hospital malnutrition in children: association with the clinical course (2013-2014) • Multi-center, randomized, double-blind comparative study to evaluate the efficacy, safety and pharmacokinetics of daptomycin compared to an active comparator in pediatric subjects with acute hematogenous osteomyelitis due to gram-positive organisms (2013-2017) • Comparative evaluation of the safety and efficacy of daptomycin compared to the standard of care in pediatric subjects of 2-17 years of age with bacteraemia caused by Staphylococcus aureus (2013-2016) • Monitoring of influenza virus infections in children (2013-2014) • Immunogenicity, safety and tolerability of influenza vaccination in children and adolescents with chronic renal failure (2013-2014) • Clinical and immunomodulatory effects of antibiotic therapy associated with pidotimod versus the only antibiotic therapy in children with community-acquired pneumonia (CAP) (2013-2015) • Assessment of pituitary function in children with infectious meningitis (2013-2014) • Use of platelet gel in the treatment of ulcerative lesions in patients with hereditary epidermolysis bullosa: evaluation of the remedial efficacy versus the gold therapeutic standards on the market and on the prevention of spino-cellular carcinomas (2013-2015) • Surveillance of respiratory syncytial virus (RSV) infection and disease in children younger than 2 years (2013-2014) • Nasopharyngeal colonization by Streptococcus pneumoniae in healthy or high-risk children and adolescents, aged between 6 and 17 years (2013-2014) • Clinical efficacy and safety of J0022X ST in the prevention of recurrent upper airway infections (2014-2016) • Phase 2/3 open-label study to evaluate pharmacokinetics, safety and antiviral activity in a single tablet regimen (STR) of elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (E / C / F / TAF) in affected adolescent patients HIV-1 naïve to antiretroviral treatment (2014-2017) • Phase 3 clinical trial, randomized, with active control, with blinded observer, to evaluate the lot correspondence, safety, tolerability and immunogenicity of rLP2086 vaccine for serogroup B meningococcus in healthy subjects aged ≥ 11 e <19 years (2014-2015) • Open-label, randomized, multicenter, phase-defining Ib study to analyze the pharmacokinetics / pharmacodynamics of oseltamivir (tamiflu) in the treatment of influenza in immunocompromised children, aged 0 to 18 years, with confirmed infection of influence (2014-2018) • Study on the efficacy and immunogenicity of the quadrivalent flu vaccine administered intramuscularly in healthy children aged between 6 and 35 months (2014-2018) • Phase IIIb multicenter, controlled, open-label study to evaluate the safety, tolerability and immunogenicity of two doses of the Novartis group B meningococcal vaccine administered to immunocompromised patients between 2 and 17 years of age who present a higher risk to develop meningococcal disease due to a complement deficiency or asplenia, compared to a control group made up of healthy subjects (2014-2015) • Study on the duration of protection from pneumococcal colonization induced by conjugate vaccines (2014-2015) • Phase 3, multicenter, randomized, double-blind, placebo-controlled study on the efficacy and safety of SD-101 in cream in patients with epidermiolysis bullosa (2014-2018) • Immunogenicity, safety and tolerability of the inactivated trivalent vaccine against influenza in obese children and adolescents (2014-2015) • Phase III clinical trial, stratified, randomized, blinded to the observer, controlled, multicenter to evaluate the safety, immunogenicity and efficacy of an adjuvanted influenza virus vaccine with a quadrivalent subunit compared to an influenza vaccine non-adjuvanted comparison in children aged ≥ 6 and <72 months (2014-2015) • Research of the autoimmune component in epidermolysis bullosa (RiCoA-EB) (2014-2016) • Phase 3 multicenter, parallel group, randomized, blinded study for the investigator, to examine the safety and efficacy of the oral suspension or fidaxomycin tablets taken every 6 hours for 10 days in pediatric subjects with diarrhea associated with Clostridium difficult (2014-2017) • Etiological role of viruses and bacteria in the child with acute respiratory failure (IRA) hospitalized in Pediatric Intensive Care (2014-2016) • Double-blind, randomized, stratified, multi-center trial for the evaluation of oseltamivir in a conventional and double dose in the treatment of influenza in immunocompromised patients (2014-2018) • Chronic cough as an indicator of Bordetella pertussis infection and as an indication of lack of vaccination coverage (2014-2017) • Surveillance for respiratory syncytial virus (RSV) infection and disease in elderly aged> 65 years (2014-2015) • Open-label multicenter study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftaroline in infants and young children with late-onset sepsis (2015-2017) • Open-label, multicenter extension study aimed at assessing the long-term safety of Zorblisa ™ (SD-101-6.0) in patients with epidermolysis bullosa (2015-2018) • Epidemiological study of the etiology of acute otitis media complicated by spontaneous perforation in children (2015-2016) • Influence of different sources of information on the acceptance of vaccinations in adolescents (2015-2016) • Randomized, double-blind clinical trial on the efficacy and tolerability of intranasal administration of rhinogermine in the prevention of acute otitis media in children with a history of recurrent acute otitis media (2015-2017) • Study of the family burden in patients with epidermolysis bullosa (2016-2018) • Evaluation of the persistence of nasopharyngeal colonization with Streptococcus salivarius 24SMB and Streptococcus oralis 89a after their administration with nasal spray for 5 and 7 days (2016-2017) • Nasopharyngeal colonization by Staphylococcus aureus in children and adolescents undergoing surgery (2015-2017) • Clinical and functional characteristics of obese pediatric patients with bronchial asthma (2016-2017) • Randomized, double-blind, placebo-controlled prospective study to evaluate the number, duration and severity of upper respiratory tract infections in children at high risk of recurrence after standard treatment with the bacterial lysate "Paspat 3 mg tablets" in the span of a six-month observation period (2016-2017) • Phase I / II multicenter clinical trial, randomized and controlled, with blinded observer, at increasing dosages, aimed at assessing the safety, reactogenicity and immunogenicity of the experimental vaccine (GSK3389245A) of GlaxoSmithKline Biologicals directed against the respiratory syncytial virus (RSV) and based on viral proteins F, N and M2-1 encoded by the adeno-carrier ChAd155-RSV, when administered intramuscularly, according to a schedule at 0, 1-months, to RSV-seropositive children aged between 12 and 17 months (2016-2017) • Phase IV, randomized, controlled, double-blind pharmacological study on the efficacy and safety of OM-85 in children with recurrent respiratory infections (2016-still ongoing) • Phase 3 study, randomization, blinded for the observer, controlled by placebo, sequential in groups for the determination of the immunogenicity and safety of a recombinant nanoparticle vaccine against respiratory syncytial virus (RSV) F with aluminum in women in the third trimester of pregnancy, and RSV disease in the newborn (2016-ongoing) • A phase 1b randomized, partially double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and tolerability of multiple doses of JNJ-53718678 administered orally in hospitalized children with VRS infection (2016-ongoing) • Phase IV, blinded, randomized, cross-over, placebo-controlled, multicenter study to evaluate the immunogenicity and safety of a single dose of Boostrix ™ in pregnant women (2016-ongoing) • Open-label, non-randomized multicenter phase IV study to evaluate the immunogenicity and safety of Infanrix hexa® when administered as primary vaccination in infants born healthy to mothers vaccinated with Boostrix® during pregnancy or postpartum in study 116945 [ DTPA (BOOSTRIX) -047] (2016-2018) • AUTOPILOT-DX: Pilot study, multicenter, prospective, to validate the diagnostic accuracy and evaluate the potential clinical utility of a diagnostic tool based on the host's response to distinguish between bacterial and viral etiologies in pediatric patients who come to the emergency room with respiratory tract infections (RTI) and fever of unknown origin (FWS) (2017-still ongoing). • INFQ3003: Phase III study, blinded for the observer, randomized, controlled with a non-flu vaccine by comparison, parallel groups, multinational conducted on children aged between 6 and 35 months to evaluate the safety and efficacy of the Abbott candidate quadrivalent flu vaccine (2017 - still ongoing) • EPID-ASTHMA: Epidemiology of bronchial asthma in adolescence (2017-still ongoing) • MAGICAL: Impact of continuous blood sugar control on metabolic control and quality of life in patients with diabetes of pediatric age in multi-injection therapy (2018) • Multicenter observational study on the management and follow-up of febrile seizures in the pediatric population belonging to the DEA of the AOY Meyer in Florence and the pediatric clinic of the AOU of Perugia (2017 - still ongoing). • Diagnostic value of presepsin in infants less than 3 months of age with fever without origin (2017 - still ongoing) • With your legs and your heart, beyond diabetes (2017) • Respiratory microbiota in children with recurrent acute otitis media (2017-still ongoing) • Immunogenicity, safety and tolerability of a quadrivalent vaccine for influenza +/- probiotics in children with type I diabetes (2017 - still ongoing) • BPA-PUBERTY: Observational study on the role of Bisphenol A and phthalates in early puberty (2017-still ongoing) • BIOMARK-ASTHMA: Biomarkers for a possible development of asthma in Umbrian children suffering from allergic rhinitis (2017-still ongoing) • SIBO-INFL: Correlation between intestinal bacterial proliferation (SIBO) and low-grade systemic inflammation in obese children (2018-still ongoing) • PED-17-05: Prospective assessment on the acceptance of vaccinations following the approval of the decree law on the vaccination obligation in children and adolescents in the Umbria region (2018-2019) • HZA107116: Randomized, double-blind, parallel group, multicenter, stratified study to evaluate the efficacy and safety of inhaled powder of fluticasone furoate / vilanterol administered once daily compared to inhaled powder of fluticasone furoate administered once. once a day in the treatment of asthma in participants aged 5 to 17 years who are currently not controlled with inhaled corticosteroids (2018-continues to this day). • RSVPED-002: Phase I / II multicenter clinical trial, randomized and controlled, with blinded observer, at increasing dosages, aimed at assessing the safety, reactogenicity and immunogenicity of the experimental vaccine (GSK3389245A) of GlaxoSmithKline Biologicals directed against the respiratory syncytial virus (RSV) is based on the viral proteins F, N and M2-1 encoded by the adeno-carrier ChAd155-RSV, when administered intramuscularly, according to a schedule at 0, 1-months, to RSV-HIV-positive children aged between 12 and 23 months (2018-continues to this day). • A multi-center, Phase I, open-label study to investigate pharmacokinetics (PK) of ticagrelor in infants and toddlers, aged 0 to 24 months, with sickle cell disease (2018-continues to this day). • DATABASE-CELIACHIA: Database for the collection of information on the methods of diagnosis of celiac disease in children and adults following the dissemination of the update of the guidelines for the diagnosis of celiac disease by the European Society of Pediatric Gastroenterology ( 2018-in progress). • HZA107116: Randomized, double-blind, parallel group, multicenter, stratified study to evaluate the efficacy and safety of the inhaled powder of fluticasone furoate / vilanterol administered once daily compared to the inhaled powder of fluticasone furoate administered once. once a day in the treatment of asthma in participants aged 5 to 17 years who are currently uncontrolled with inhaled corticosteroids (2018-ongoing). • RSVPED-002: Phase I / II multicenter clinical trial, randomized and controlled, with blinded observer, at increasing dosages, aimed at assessing the safety, reactogenicity and immunogenicity of the experimental vaccine (GSK3389245A) of GlaxoSmithKline Biologicals directed against the respiratory syncytial virus (RSV) is based on the viral proteins F, N and M2-1 encoded by the adeno-carrier ChAd155-RSV, when administered intramuscularly, according to a schedule at 0, 1-months, to RSV-HIV-positive children aged between 12 and 23 months (2017-ongoing). • HESTIA4: A multi-center, Phase I, open-label study to investigate pharmacokinetics (PK) of ticagrelor in infants and toddlers, aged 0 to 24 months, with sickle cell disease (2018-in progress). • 63623872FLZ3001: A Phase 3 Randomized, doubleblind, placebocontrolled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ63623872 in Combination With Standard of care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection (2018-in progress). • 63623872FLZ3002: A phase 3 randomized, doubleblind, placebocontrolled, multicenter study to evaluate the efficacy and safety of jnj63623872 in combination with standardofcare treatment in adolescent, adult, and elderly nonhospitalized patients with influenza a infection who are at risk of developing complications (2018- in progress). • V114-023: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children with Sickle Cell Disease (PNEU – SICKLE) (2018-ongoing) . • MET58: Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (2018-ongoing). Management of magazines, editorial series, encyclopedias and treatises of recognized prestige • Collaboration in the direction of the Italian Journal of Pediatric Infectivology (from January 1, 2001 to December 31, 2010); • Editor of Edit Symposia magazine (from 1 January 2016). Participation in editorial committees of magazines, editorial series, encyclopedias and treaties of recognized prestige • Member of the Pediatric Area Editorial Board (from 1 January 2001 to 31 December 2007). • Collaboration in the management of Vaccinare Oggi & Domani (from 1 March 2002 to 31 December 2016). • International Editor of The Pediatric Infectious Disease Journal (since May 1, 2005 and still continues). • Assistant Editor of The International Journal of Pediatric Infectious Diseases (from January 1, 2006 to December 31, 2007). • Editorial Board Member of The International Journal of Pediatric Infectious Diseases (from January 1, 2008). • Associate Editor of BMC Infectious Diseases (from 1 October 2009 and continues to this day). • Associate Editor of Human Vaccines & Immunotherapeutics (from January 1, 2011 and continues today). • Associate Editor of Journal of Clinical Virology (from January 1, 2013 and continues today). • Editorial Board Member of PLOS One (from 1 August 2013). • Associate Editor of Medicine (from 1 July 2014). • Editorial Board Member of AIMS Microbiology (from May 1, 2016). • Editorial Board Member of Npj Vaccines (from 1 July 2016). • Editorial Board Member of Current Pharmaceutical Design (since February 2018 and continues to this day). • Editorial Board Member of the International Journal of Environment Research and Public Health (since March 2018 and continues to this day); • Pneumonia Editorial Board Member (since April 2019 and continues to this day). • Editorial Board Member of Frontiers in Pediatrics (since September 2019 and continues today). Editorial Board Member of Expert Review in Anti-Infective Therapy (since November 2019 and continues to this day). Ongoing referee activity for scientific journals on articles related to pediatrics American Journal of Physicians; BMC Infectious Diseases; BMC Public Health; British Medical Journal; Chest; Clinical Drug Investigation; Drugs; European Journal of Pediatrics; European Respiratory Joiurnal; European Journal of Clinical Microbiology and Infectious Diseases; Human Vaccines & Immunotherapeutics; Infection; Italian Journal of Pediatrics; Journal of Chemotherapy; Journal of Clinical Virology; Journal of Infection; Journal of Pediatric Gastroenterology and Nutrition; Lancet; Lancet Infectious Diseases; Medicine; Minerva Pediatrica; Pediatric Drugs; Pediatric Health; Pediatric Pulmonology; Pediatrics; Plos One; Respiratory Medicine; Respiratory Research; The International Journal of Pediatric Infectious Diseases; The Pediatric Infectious Disease Journal; Thorax; Trends in Respiratory Medicine; Vaccine. Assignment of official teaching or research assignments (fellowships) at universities and research institutes, foreign and international, of high qualification • From the academic year 2009-2010 (continues to this day) she participates as a teacher at the Pediatric Infectious Diseases Diploma of the University of Oxford, UK. • In the 2013-2014 academic year, she was called as external professor by the University of Geneva to select pediatric professors. Management of high internationally qualified research bodies or institutes • President of the Commission of the World Health Organization (WHO) for the eradication of measles and congenital rubella (from 1 January 2012 to 31 December 2015) and then Past-President of the Commission (from 1 January 2016 to 31 December 2018). Participation in academies with prestige in the sector International academies • Representative for the pediatric section in the "Share- The IAS educational program on HIV clinical care" (from 1999 to 2002). • Member of the Board of Directors of the European Society for Pediatric Infectious Diseases (ESPID) (from 2004 to 2007). • Member of the Committee for Training of the European Society for Pediatric Infectious Diseases (ESPID) (2007-2013). • Member of the Committee for Research of the European Society for Pediatric Infectious Diseases (ESPID) (2007-2013). • Member of the Steering Committee of the Pediatric European Network for the Treatment of Infection (PENTi) (from 2008 to 2013). • Member of the Steering Committee of the European Center for Diseases Control (ECDC) for Pneumococcal Vaccination Guidance (from 2009 to 2014). • External Expert for the European Medicines Agency (EMA) on the topic "Correlates for protection and serological assays on influenza vaccines" (in May 2012). • Chairperson of the vaccine study group for the European Society for Clinical Microbiology and Infectious Diseases (EVASG-ESCMID; from 1 May 2013 and continues to this day). • VaccineXpert.net Board Member (since May 2014 and still continues). • President of the World Association for Infectious Diseases and Immunological Disorders (since May 2014 and continues to this day); • Member of the Independent Data Monitoring Committee of ertapenem (in 2014); • Member of the Bedaquilina Independent Data Monitoring Committee (since September 2014 and continues to this day); • Reference pediatrician for tuberculosis therapy for the European Respiratory Society (WHO Consilium: from April 1, 2016 and continues today). • Member of the Global Pneumonia Prevention Coalition (since December 2015 and continues to this day); • Member of the ESCMID Global Alliance for Infections in Surgery (since January 2017 and continues to this day); • IDMC for Janssen on new antiviral drugs on RSV (since January 2017 and continues to this day); • ECDC expert on RSV and enterovirus surveillance in Europe, 7-8 February 2017; • Founding partner of INCiPIT (Italian Network for Pediatric Clinical Trials) as representative of the University of Perugia since 2017; • Member of the Steering Group on Influenza Vaccination for increasing immunization coverage across Europe (since October 2017 and continues to this day); • Member of the Pneumonia Innovations Network (since January 2018 and continues to this day). National academies • Member of the Board of Directors of the Italian Society of Pediatric Infectivology (from 2002 to 2005). • Member of the Board of Directors of the Italian Society of Pediatrics - Lombard Section (from 2004 to 2006). • Member of the Vaccine Commission of the Italian Society of Immunology and Pediatric Allergology (from 2004 to 2018). • Treasurer of the Italian Society of Pediatric Infectivology (from 2005 to 2008). • Scientific Secretary of the Antibiotics Commission of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan (from 2005 to 2017). • Member of the Committee for the Prevention and Control of Hospital Infections of the IRCCS Ca 'Granda Hospital Maggiore Policlinico Foundation, Milan (from 2005 to 2017). • Commissioner of the Teaching Evaluation Commission of the University of Milan (from 2005 to 2009). • Commissioner of the Polo Educational Commission - Central Pole of the University of Milan (from 2005 to 2009). • Secretary of the Italian Society of Preventive and Social Pediatrics (from 2008 to 2012). • Contact person of the "Correct use of medicines" working group of the Italian Society of Preventive and Social Pediatrics (from 2008 to 2012). • Referent of the "Vaccinations" working group of the Italian Society of Preventive and Social Pediatrics (from 2008 to 2012). • Vice-President of the Italian Society of Pediatric Infectivology (from 2008 to 2011). • Member of the Board of Directors of the Italian Society of Sexually Transmitted Diseases (since 2012 and still continues); • President of the Italian Society of Pediatric Infectivology (from 2011 to 2015). • Member of the Board of Directors of the Italian Society of Pediatric Research (from 2012 to 2015). • Member of the Medicines Commission of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan (from 2014 to 2017). • Member of the Healthcare Research & Pharmacoepidemiology Center (since 2016 and continues to this day); • Member of the Scientific Committee of the Italian Registry for Epidermolysis Bollosa (since 2017 and continues to this day); • Pediatrician referent for the Chronicity Plan of the Umbria Region (from 2017 to 2019); • Member of the SIP Vaccine Commission (since February 2017 and continues to this day); • Member of the Vaccine Commission of Umbria (from October 2017 to August 2019); • Member of the Academy of Sciences of Umbria (since November 2017 and continues to this day); • Founding partner of INCiPIT (Italian Network for Pediatric Clinical Trials) as representative of the University of Perugia since 2017; • Member of the Steering Group on Influenza Vaccination for increasing immunization coverage across Europe (since October 2017 and continues to this day); • Member of the Pneumonia Innovations Network (since January 2018 and continues to this day). National academies • Member of the Board of Directors of the Italian Society of Pediatric Infectivology (from 2002 to 2005). • Member of the Board of Directors of the Italian Society of Pediatrics - Lombard Section (from 2004 to 2006). • Member of the Vaccine Commission of the Italian Society of Immunology and Pediatric Allergology (from 2004 to 2018). • Treasurer of the Italian Society of Pediatric Infectivology (from 2005 to 2008). • Scientific Secretary of the Antibiotics Commission of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan (from 2005 to 2017). • Member of the Committee for the Prevention and Control of Hospital Infections of the IRCCS Ca 'Granda Hospital Maggiore Policlinico Foundation, Milan (from 2005 to 2017). • Commissioner of the Teaching Evaluation Commission of the University of Milan (from 2005 to 2009). • Commissioner of the Polo Educational Commission - Central Pole of the University of Milan (from 2005 to 2009). • Secretary of the Italian Society of Preventive and Social Pediatrics (from 2008 to 2012). • Contact person of the "Correct use of medicines" working group of the Italian Society of Preventive and Social Pediatrics (from 2008 to 2012). • Referent of the "Vaccinations" working group of the Italian Society of Preventive and Social Pediatrics (from 2008 to 2012). • Vice-President of the Italian Society of Pediatric Infectivology (from 2008 to 2011). • Member of the Board of Directors of the Italian Society of Sexually Transmitted Diseases (since 2012 and still continues); • President of the Italian Society of Pediatric Infectivology (from 2011 to 2015). • Member of the Board of Directors of the Italian Society of Pediatric Research (from 2012 to 2015). • Member of the Medicines Commission of the IRCCS Ca 'Granda Maggiore Policlinico Hospital, Milan (from 2014 to 2017). • Member of the Healthcare Research & Pharmacoepidemiology Center (since 2016 and continues to this day); • Member of the Scientific Committee of the Italian Registry for Epidermolysis Bollosa (since 2017 and continues to this day); • Pediatrician referent for the Chronicity Plan of the Umbria Region (from 2017 to 2019); • Member of the SIP Vaccine Commission (since February 2017 and continues to this day); • Member of the Vaccine Commission of Umbria (from October 2017 to August 2019); • Member of the Academy of Sciences of Umbria (since November 2017 and continues to this day); • Member of the Executive Committee of the Italian Network for Pediatric Clinical Trials (INCiPiT) Consortium (since February 2018 and continues to this day); • President of the Italian Society of Emergency Medicine-Pediatric Emergency (SIMEUP) - Umbria Section (from February 2018 to August 2019); • Member of the GISA Antimicrobial Stewardship (since February 2018 and continues to this day); • Member of the Scientific Committee of the Interuniversity Research Center on Pollution and the Environment (CIRIAF; from April 2018 to August 2019); • Responsible for the University of Perugia of the Framework Agreement between the University of Perugia and the European Bio Molecular Institute (ISBEM); • Member of the Council of the Interdepartmental Research Center for Motor Activities, Obesity, Diabetes, Hypertension, Arteriosclerosis, Osteoporosis (C.U.R.I.A.M.O .: from February 19, 2019 to August 31, 2019). Obtaining prizes and awards for scientific activity • "Carlo Imperato" Prize, awarded by the President of the Italian Society of Pediatrics on the occasion of the 58th National Congress of the Italian Society of Pediatrics (Montecatini, 28 September-2 October 2002), for the best experimental work on the topic of "Respiratory diseases of the child". • Young Investigator Award, presented by the Chairman of the III World Congress of Pediatric Infectious Diseases (Santiago, Chile, November 19-23 2002), for the work "Minimum protective serum concentrations of pneumococcal anti-capsular antibodies against pneumonia". • "George McCracken Fellowship" title, received at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (Chicago, Illinois, September 14-17 2003). • Young Scientist Grant, delivered by the Chairman of the Options for the Control of Influenza V (Okinawa, Japan, October 7-11 2003). • Amici di Milano Prize - Gold Medals awarded the Silver Plaque of the President of the Italian Republic and the Silver Plaque of the President of the Lombardy Region, awarded by the Mayor of Milan on March 24, 2004, as the best medical researcher. • SIP 2008 Members Award, as the best researcher in general and specialist pediatrics within the Italian Society of Pediatrics, awarded during the inaugural ceremony of the 64th Congress of the Italian Society of Pediatrics on October 15, 2008 in Genoa. • Ambassador Award for research abroad in the medical field delivered by the Honorable Maurizio Lupi on May 21, 2011 in Milan. • Certificate of merit for the commitment and professionalism demonstrated over the years dedicated to the health of the child - Association of Friends of the Polyclinic and Mangiagalli (November 30, 2014). • Appointment of ESCMID Fellow on April 24, 2017 "for outstanding service to the profession and the society". Other titles • President of Friends of the Sick Child (ABM) Onlus (since 2009 and still continues). • Member of the Rare Diseases Unit of the IRCCS Ca 'Granda Ospedale Maggiore Policlinico Foundation in Milan (from January 2013 to December 31, 2017). • Member of the Milan Area B Ethics Committee (from 1 September 2013 to 31 December 2017). • Member of the GAT Sepsi Regione Lombardia (in 2014). • Reviewer of CINECA research projects (since 2013 and continues to this day). • Reviewer of research grants of the University of Padua and the University of Insubria (in the academic year 2014-2015). • Reviewer of research projects of the Experimental Zooprophylactic Institute of Venice (Legnago; in 2014), of the Children's Hospital of Harvard University (Boston, USA; in 2015) and of the National Science Center of Poland (in 2015). • ERC Starting Grant Project Reviewer (2017). • Review Grant Meningitis Research Foundation, University College, London (2017). International Congress Organization • Since 2004, she participates every year in the organization of the Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) and was the President of the 31st ESPID Annual Meeting (Milan, 28 May-1 June 2013). • In March 2007 and November 2009 she organized the Advances in Pediatric Infectious Diseases course for the European Society for Pediatric Infectious Diseases (ESPID) in Milan. • she organized the Collaborative Research Meeting of the European Society for Pediatric Infectious Diseases (ESPID) in Milan in September 2008 and September 2011. • From 2009 to 2011 she organized the ESPID Research Masterclass. • In 2015 the 3rd Conference on Vaccines of the European Society for Clinical Microbiology and Infectious Disease (ESCMID) from 6 to 8 March 2015 in Lisbon, Portugal. • In 2016 she organized the 1st Congress of the World Association for Infectious Diseases and Immunological Disorders (WAidid) in Milan from 18 to 20 February; • In 2017, she organized the 4th ESCMID Conference on Vaccines - New and old diseases in children and adults - unmet needs from 8 to 10 September in Dubrovnik, Croatia. • In 2018 she organized the Congress of the World Association for Infectious Diseases and Immunological Disorders (WAidid) in Milan from 18 to 20 October. • In 2019 she organized the 5th ESCMID Conference on Vaccines against respiratory infections: new insights and new vaccines in Bilbao, Spain, from 6 to 8 September. Organization of National Congresses • Since 2000, she participates every year in the organization of the National Congress of Antibiotic Therapy in Pediatric Age, of which she has been co-president since 2011. • From 2002 to 2015 she participated every year in the organization of the National Congress of the Italian Society of Pediatric Infectivology (SITIP) and was the President of the 11th SITIP National Congress in Milan in November 2011. • From 2008 to 2012 she participated every year in the organization of the National Congress of the Italian Society of Preventive and Social Pediatrics. I authorize the use of my personal details solely for circulation within the company according to legge 196/2003 and to Regulation EU GDPR number 2016/679 Article 13.
